• Entity registrant name: Midatech Pharma Plc (CIK: 0001643918)
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1643918/000121465918002960/0001214659-18-002960-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1643918/000121465918002960/mtph-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • XBRL Cloud Rendering (requires license): Click to open XBRL Cloud Component Rendering
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001643918
  • Open this page in separate window: Click
  • * * *

    Component: (Network and Table)
    Network
    00000002 - Statement - Consolidated statements of comprehensive income
    (http://mtph/role/StatementsOfComprehensiveIncome)
    Table (Implied)
    Slicers (applies to each fact value in each table cell)
    Profit or loss [abstract] Period [Axis]
    2017-01-01 - 2017-12-31
    2016-01-01 - 2016-12-31
    2015-01-01 - 2015-12-31
    Profit or loss [abstract]
     
     
     
    Revenue
    6,758,000  
    6,376,000  
    775,000  
    Grant revenue
    840,000  
    547,000  
    600,000  
    Total revenue
    7,598,000  
     
    6,923,000  
     
    1,375,000  
     
    Cost of sales
    (926,000) 
    (667,000) 
    (70,000) 
    Gross profit
    6,672,000  
     
    6,256,000  
     
    1,305,000  
     
    Research and development costs (reclassified)
    (10,185,000) 
    (7,796,000) 
    (8,710,000) 
    Distribution costs, sales and marketing (reclassified)
    (9,417,000) 
    (12,510,000) 
    (605,000) 
    Administrative costs (reclassified)
    (3,148,000) 
    (5,123,000) 
    (4,908,000) 
    Impairment of intangible assets
    (1,500,000) 
    (11,413,000) 
    xsi:nil  
    Loss from operations
    (17,578,000) 
     
    (30,586,000) 
     
    (12,918,000) 
     
    Finance income
    415,000  
    1,337,000  
    1,691,000  
    Finance expense
    (166,000) 
    (73,000) 
    (5,000) 
    Loss before tax
    (17,329,000) 
     
    (29,322,000) 
     
    (11,232,000) 
     
    Taxation
    1,265,000  
    9,160,000  
    1,133,000  
    Loss for the year attributable to the owners of the parent
    (16,064,000) 
     
    (20,162,000) 
     
    (10,099,000) 
     
    Other comprehensive income:
     
     
     
    Items that will or may be reclassified subsequently to profit or loss when specific conditions are met:
     
     
     
    Exchange gains/(losses) arising on translation of foreign operations
    (1,233,000) 
    3,228,000  
    399,000  
    Total other comprehensive (loss) income, net of tax
    (1,233,000) 
     
    3,228,000  
     
    399,000  
     
    Total comprehensive loss attributable to the owners of the parent
    (17,297,000) 
     
    (16,934,000) 
     
    (9,700,000) 
     
    Loss per share
     
     
     
    Basic and diluted loss per ordinary share - pence
    (31) 
    (56) 
    (36)